{"id":19478,"date":"2019-02-28T11:05:48","date_gmt":"2019-02-28T11:05:48","guid":{"rendered":"https:\/\/positivelysharing.wordpress.com\/?p=19478"},"modified":"2019-02-28T11:05:48","modified_gmt":"2019-02-28T11:05:48","slug":"cytodyn-to-present-data-on-monoclonal-antibody-treatment-of-hiv-at-seattle-conference","status":"publish","type":"post","link":"https:\/\/positivelysharing.org\/blog\/2019\/02\/28\/cytodyn-to-present-data-on-monoclonal-antibody-treatment-of-hiv-at-seattle-conference\/","title":{"rendered":"CytoDyn to present data on monoclonal antibody treatment of HIV at Seattle conference"},"content":{"rendered":"Reading Time: <\/span> < 1<\/span> minute<\/span><\/span>

\"A<\/a><\/p>\n

CytoDyn<\/a>\u00a0Inc (OTCMKTS:CYDY<\/a>) said Wednesday that data from the study of its monoclonal antibody treatment of HIV will be presented at a Seattle conference.<\/p>\n

The biotech company said in a statement that the data will be presented at the Conference on Retroviruses and Opportunistic Infections on March 7.<\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n

The company\u2019s leronlimab candidate is a once-weekly injection designed to block HIV-1 from entering and infecting human cells by binding to the CCR5 receptor, a protein on the surface of white blood cells that is related to the immune system.\u00a0 Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Reading Time: <\/span> < 1<\/span> minute<\/span><\/span>CytoDyn\u00a0Inc (OTCMKTS:CYDY) said Wednesday that data from the study of its monoclonal antibody treatment of HIV will be presented at a Seattle…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":{"0":"post-19478","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-hiv"},"jetpack_featured_media_url":"","amp_enabled":true,"_links":{"self":[{"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/posts\/19478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/comments?post=19478"}],"version-history":[{"count":0,"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/posts\/19478\/revisions"}],"wp:attachment":[{"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/media?parent=19478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/categories?post=19478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/positivelysharing.org\/blog\/wp-json\/wp\/v2\/tags?post=19478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}